Executive Summary
A cluster of 12 8-K filings on February 10, 2026, signals heightened USA M&A and takeover activity, dominated by 8 SPAC/acquisition corporations (EQV Ventures, StoneBridge II, byNordic, Jackson II, EGH, Iris II, Cambridge, Hall Chadwick) announcing mergers under Items 8.01/9.01, alongside 4 operating company deals (Hillenbrand, Dynavax, La Rosa, BiomX) reporting acquisitions completions (Item 2.01). Critical red flags include 3 delisting notices (Hillenbrand, Dynavax, Jackson Acquisition II; Items 3.01) and 2 changes in control (Hillenbrand, Dynavax; Item 5.01), suggesting potential take-private transactions or compliance failures amid M&A. Sentiments skew neutral (8/12) to mixed (2/12) or bearish (1/12), with high materiality (7+ score) in 7 filings averaging 8.1/10, but no quantitative deal valuations/terms disclosed across all, increasing uncertainty. No period-over-period trends, insider trades, or forward-looking guidance provided in summaries, limiting growth/margin insights but highlighting portfolio-level SPAC de-SPAC momentum. Implications: Near-term catalysts from Item 9.01 exhibits and follow-on proxy filings; watch for shareholder dilution via equity sales (e.g., Cambridge Item 3.02) and post-merger integrations.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from February 08, 2026.
Investment Signals(12)
- Hillenbrand, Inc.β(BULLISH)β²
Completed acquisition (Item 2.01) with new material agreement (Item 1.01), high materiality 10/10 despite mixed sentiment
- Dynavax Technologies Corpβ(BULLISH)β²
Acquisition completion (Item 2.01) and new agreement (Item 1.01), materiality 10/10 signals strategic expansion
- La Rosa Holdings Corp.β(BULLISH)β²
Material definitive agreement (Item 1.01) + acquisition completion (Item 2.01), materiality 9/10 with neutral sentiment
- BiomX Inc.β(BULLISH)β²
Acquisition completion (Item 2.01) + director elections (Item 5.02), materiality 7/10 indicates operational continuity post-deal
- EQV Ventures Acquisition Corpβ(BULLISH)β²
Merger/acquisition event (Item 8.01/9.01), unlocks SPAC value creation potential
- StoneBridge Acquisition II Corpβ(BULLISH)β²
Merger announcement (Item 8.01), medium risk but opportunity for de-SPAC upside
- Iris Acquisition Corp IIβ(BULLISH)β²
Merger event (Item 8.01/9.01), materiality 7/10 higher than peers like byNordic (3/10)
- Cambridge Acquisition Corpβ(BULLISH)β²
Material agreement (Item 1.01) + equity sales (Item 3.02), materiality 8/10 supports deal funding
- byNordic Acquisition Corpβ(BULLISH)β²
Potential merger (Item 8.01/9.01), low risk profile vs sector delisting risks
- EGH Acquisition Corpβ(BULLISH)β²
Reg FD disclosure (Item 7.01) on merger, provides transparency edge
- Jackson Acquisition Co IIβ(BEARISH)β²
Delisting notice (Item 3.01) amid acquisition context, bearish liquidity risk despite 9/10 materiality
- Hall Chadwick Acquisition Corpβ(BEARISH)β²
Director changes (Item 5.02) only, low materiality 2/10 lacks M&A momentum
Risk Flags(10)
- Hillenbrand, Inc./Delistingβ[HIGH RISK]βΌ
Notice of delisting (Item 3.01) + change in control (Item 5.01), high risk erodes liquidity
- Dynavax Technologies Corp/Control Changeβ[HIGH RISK]βΌ
Change in control (Item 5.01) + delisting (Item 3.01) + rights modifications (Item 3.03), high risk to shareholders
- Jackson Acquisition Co II/Delistingβ[HIGH RISK]βΌ
Failure to satisfy listing standards (Item 3.01), bearish sentiment + high risk/9/10 materiality
- Hillenbrand, Inc./Financial Obligationsβ[MEDIUM RISK]βΌ
New financial obligations (Item 2.03) post-acquisition, undisclosed terms amplify leverage risk
- Dynavax Technologies Corp/Terminationβ[MEDIUM RISK]βΌ
Prior agreement terminated (Item 1.02) + security rights changes (Item 3.03), mixed sentiment high risk
- La Rosa Holdings Corp/Integrationβ[MEDIUM RISK]βΌ
Acquisition complete (Item 2.01) but unknown terms/parties, medium risk on financial impact
- BiomX Inc./Leadership Turnoverβ[MEDIUM RISK]βΌ
Director/officer departures (Item 5.02) post-acquisition, undisclosed details heighten execution risk
- StoneBridge Acquisition II Corp/Uncertaintyβ[MEDIUM RISK]βΌ
No deal details disclosed, medium risk/uncertainty on valuation/execution
- Iris Acquisition Corp II/Disclosure Gapβ[MEDIUM RISK]βΌ
Merger (Item 8.01) lacks structure/parties, medium risk vs higher materiality peers
- Cambridge Acquisition Corp/Dilutionβ[MEDIUM RISK]βΌ
Unregistered equity sales (Item 3.02), potential shareholder dilution in merger context
Opportunities(10)
- Hillenbrand, Inc./Takeover Arbitrageβ(OPPORTUNITY)β
Change in control + acquisition complete, high materiality 10/10 for potential premium realization
- Dynavax Technologies Corp/Biotech M&Aβ(OPPORTUNITY)β
Acquisition (Item 2.01) + control shift, 10/10 materiality undervalued if synergies emerge
- La Rosa Holdings Corp/Post-Merger Growthβ(OPPORTUNITY)β
Deal completion (Item 2.01), 9/10 materiality for integration alpha vs neutral peers
- BiomX Inc./Asset Acquisitionβ(OPPORTUNITY)β
Completion (Item 2.01) + new leadership (Item 5.02), 7/10 materiality biotech pipeline expansion
- EQV Ventures Acquisition Corp/SPAC De-SPACβ(OPPORTUNITY)β
Merger event (Item 8.01), low risk entry to target company exposure
- StoneBridge Acquisition II Corp/Merger Upsideβ(OPPORTUNITY)β
Announcement (Item 8.01), pending terms disclosure offers value creation
- Iris Acquisition Corp II/High Materiality Mergerβ(OPPORTUNITY)β
Item 8.01 event at 7/10 materiality outperforms low-score SPACs like byNordic
- Cambridge Acquisition Corp/Deal Momentumβ(OPPORTUNITY)β
Material agreement (Item 1.01) + exhibits (9.01), 8/10 materiality for early positioning
- byNordic Acquisition Corp/Low Risk Entryβ(OPPORTUNITY)β
Neutral merger filing (Item 8.01), 3/10 materiality but lower risk than delisting peers
- EGH Acquisition Corp/Reg FD Alphaβ(OPPORTUNITY)β
Item 7.01 disclosure provides edge on merger details vs non-FD peers
Sector Themes(6)
- SPAC Merger Surgeβ
8/12 filings from acquisition corps (e.g., EQV, StoneBridge, Iris) under Item 8.01/9.01 on same day, signals accelerated de-SPAC activity; implications: liquidity events for SPAC holders, watch redemptions.
- Delisting Clusters in M&Aβ
3/12 (25%) report Item 3.01 (Hillenbrand, Dynavax, Jackson), tied to control changes; avg high materiality 9.7/10, suggests take-private trend reducing public float.
- Acquisition Completions Waveβ
4/12 (33%) disclose Item 2.01 completions (Hillenbrand, Dynavax, La Rosa, BiomX), neutral/mixed sentiment but high materiality avg 9/10; portfolio signal of deal execution momentum.
- Control & Rights Changesβ
2 high-risk cases (Hillenbrand, Dynavax) with Item 5.01/3.03, mixed sentiment; cross-filings pattern indicates shareholder rights dilution in takeovers.
- Biotech M&A Momentumβ
Dynavax/BiomX show acquisitions + leadership shifts, higher materiality (10/10, 7/10) vs SPACs; potential sector consolidation without disclosed valuations.
- Disclosure Gaps Across Boardβ
12/12 lack quantitative terms/valuations/parties, neutral sentiment dominant (67%); implications: review Item 9.01 exhibits for alpha, high uncertainty favors patient investors.
Watch List(8)
Monitor follow-on filings for delisting transfer (Item 3.01) + control details (Item 5.01), post-2/10/2026.
Track security rights mods (Item 3.03) + acquisition exhibits (Item 9.01), biotech synergies reveal Q1 2026.
Watch remediation or transfer post-delisting notice (Item 3.01), liquidity impact imminent.
Review Item 9.01 exhibits for undisclosed acquisition valuation/integration risks, high 9/10 materiality.
Monitor post-acquisition director changes (Item 5.02) for execution signals, biotech focus.
Equity sales (Item 3.02) + material agreement (1.01), watch proxy for approval timeline.
Item 8.01 details pending, 7/10 materiality vs peers, track execution vs uncertainty.
Merger announcement (8.01), monitor for terms disclosure to assess value creation.
Filing Analyses(12)
10-02-2026
Hillenbrand, Inc. disclosed in its 8-K filing the entry into a new material definitive agreement (Item 1.01) and termination of a prior material definitive agreement (Item 1.02), alongside completion of an acquisition or disposition of assets (Item 2.01). The filing also reports creation of direct financial obligations (Item 2.03), notice of delisting or failure to satisfy listing standards (Item 3.01), material modifications to security holder rights (Item 3.03), changes in control of the registrant (Item 5.01), and changes in directors/officers including compensatory arrangements (Item 5.02), with partial mention of amendments to articles of incorporation (Item 5.03). No quantitative financial terms, parties involved, or specific impacts are disclosed.
10-02-2026
EQV Ventures Acquisition Corp. filed an 8-K on 2026-02-10 disclosing other events under Item 8.01 and financial statements and exhibits under Item 9.01 in connection with a merger/acquisition event. No specific deal structure, parties, valuation, financial metrics, or performance comparisons are explicitly stated in the provided filing information. Sector is not specified.
10-02-2026
StoneBridge Acquisition II Corp filed an 8-K on February 10, 2026 (AccNo: 0001829126-26-001192) under Item 8.01 Other Events announcing a Merger/Acquisition event. No specific details on deal structure, parties involved, valuation, financial terms, or impacts are disclosed in the provided filing summary. Sector is not specified, and no quantitative metrics, positive or negative changes, or scheduled events are mentioned.
10-02-2026
La Rosa Holdings Corp. filed an 8-K on 2026-02-10 (AccNo: 0001213900-26-014257) disclosing under Item 1.01 its entry into a material definitive agreement and under Item 2.01 the completion of an acquisition or disposition of assets. Item 9.01 provides financial statements and exhibits. No specific details on deal structure, parties, valuation, terms, or financial impacts were disclosed.
10-02-2026
byNordic Acquisition Corp filed an 8-K on 2026-02-10 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), potentially related to a merger or acquisition announcement. No specific details on parties, structure, valuation, or financial metrics are disclosed in the provided filing information. File size is 259 KB with AccNo 0001213900-26-014250; sector not specified.
10-02-2026
Jackson Acquisition Co II filed an 8-K on February 10, 2026, under Item 3.01 disclosing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing, which signals potential liquidity and compliance risks with no further details provided. Item 9.01 includes financial statements and exhibits, but no quantitative metrics, deal specifics, or positive developments are mentioned. No positive or flat metrics are disclosed to offset the negative listing notice.
10-02-2026
BiomX Inc. filed an 8-K on February 10, 2026, reporting the completion of an acquisition or disposition of assets under Item 2.01. The filing also covers departures of directors or certain officers, elections of directors, appointments of certain officers, and compensatory arrangements under Item 5.02. Financial statements and exhibits are included under Item 9.01, with no specific transaction details, parties, values, or metrics disclosed.
10-02-2026
EGH Acquisition Corp. filed an 8-K on 2026-02-10 (AccNo: 0001104659-26-012621, Size: 401 KB) disclosing information under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on merger/acquisition structure, parties, valuation, financial metrics, or performance comparisons are provided in the filing summary. All quantitative data, named parties beyond the filer, and transaction terms are NOT_DISCLOSED.
10-02-2026
Iris Acquisition Corp II filed an 8-K on February 10, 2026 (AccNo: 0001185185-26-000487, Size: 423 KB), disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01 in connection with a merger/acquisition event. No specific deal structure, parties involved, valuation, financial terms, synergies, regulatory details, or shareholder impacts are disclosed. Sector is not specified, and no quantitative metrics or comparisons are provided.
10-02-2026
Cambridge Acquisition Corp. filed an 8-K on 2026-02-10 disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws and/or change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No quantitative metrics, financial terms, parties involved, deal structure, or performance comparisons are explicitly stated. This filing indicates a merger/acquisition event but lacks details for comprehensive assessment.
10-02-2026
Hall Chadwick Acquisition Corp filed an 8-K on 2026-02-10 under Item 5.02, disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific names, dates, financial details, transaction information, or quantitative metrics are mentioned in the filing details provided. No merger or acquisition is referenced in the disclosed Item.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 12 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings β March 24, 2026
US Corporate Distress Financial Stress SEC Filings